Overall, these findings provide a comprehensive portrait of the distinctive impact of CHK2 dysregulation on the evolution of premenopausal, metastatic, highly PR+, ER+/HER2− breast cancer that is likely to resist standard endocrine monotherapies. This evidence concerns the gene PGR and breast cancer.